¿°Áõ¼ö¿ëü/¸®°£µå¸¦ Ÿ±êÀ¸·Î ÇÑ ºñ¸¸¼º ¿°Áõ/´ë»çÁúȯ Á¦¾î
Inflammatory Receptors/Ligands as a Novel Target Against Obesity-Induced Inflammation and Metabolic Diseases
´ëÇѺñ¸¸ÇÐȸÁö 2014³â 23±Ç 2È£ p.83 ~ p.90
À¯¸®³ª(Yu Ri-Na) - ¿ï»ê´ëÇб³ ½ÄÇ°¿µ¾çÇаú
Abstract
ºñ¸¸À¸·Î À¯µµµÈ ¿°ÁõÀº Àν¶¸° ÀúÇ×¼º, Á¦2Çü ´ç´¢, µ¿¸Æ°æÈ¿Í °° Àº ºñ¸¸¼º ´ë»çÁúȯÀÇ ¹ß»ý¿øÀÎ ¶Ç´Â ÃËÁøÀÚ ¿ªÇÒÀ» ÇÑ´Ù. ºñ¸¸¼º ¿° Áõ¹ÝÀÀÀ» ¸Å°³ÇÏ´Â ¿©·¯ °¡Áö ¿°Áõ ±¸¼º¿ä¼ÒµéÀÌ ¾Ë·ÁÁ® ÀÖÀ½¿¡µµ ºÒ±¸ÇÏ°í ºñ¸¸¼º ¿°Áõ/´ë»çÁúȯÀ» À¯µµ/Á¶ÀýÇÏ´Â »ýüºÐÀÚ¿Í ±× ¸Þ Ä¿´ÏÁò¿¡ ´ëÇؼ´Â ¾ÆÁ÷ ¸ð¸£´Â Á¡ÀÌ ¸¹´Ù. ¸é¿ª¼¼Æ÷ Ç¥¸é¿¡ Á¸ÀçÇÏ´Â ¸· ¼ö¿ëüÀÎ Tumor Necrosis Factor Receptor Superfamily (TNFRSF) ¿Í ±× ¸®°£µåµéÀº ¿°Áõ¹ÝÀÀ À¯µµ/Á¶Àý¿¡ Áß¿äÇÑ ½ÅÈ£¸¦ Á¦°øÇϸç, ´Ù ¾çÇÑ ¿°Áõ¼º ÁúȯÀÇ Ä¡·á¸¦ À§ÇÑ Å¸±ê ºÐÀÚ·Î È°¿ëµÈ´Ù. ÃÖ±Ù ÀÌµé ¿° Áõ¼ö¿ëü/¸®°£µå°¡ ºñ¸¸¼º Áö¹æÁ¶Á÷ ¿°Áõ¹ÝÀÀÀ» Á¶ÀýÇϸç, ÀÌµé ºÐ ÀÚµéÀÇ »óÈ£ÀÛ¿ëÀÇ Â÷´ÜÀÌ ºñ¸¸¼º ¿°Áõ/´ë»çÁúȯÀÇ °³¼±À» °¡Á®¿Â´Ù °í º¸°íµÇ°í ÀÖ´Ù. º» ¹Ì´Ï¸®ºä¿¡¼´Â ºñ¸¸¼º ¿°Áõ/´ë»çÁúȯ¿¡ °ü¿© ÇÏ´Â ³× Á¾·ùÀÇ ¿°Áõ¼ö¿ëü/¸®°£µå(CD40/CD40L, 4-1BB/4-BBL, FN14/TWEAK, HEVM/LIGHT)µé¿¡ ´ëÇØ »ìÆ캸°í, ÀÌµé ºÐÀÚµéÀÌ ºñ¸¸¼º ¿°Áõ ¹× ´ë»çÁúȯ Á¦¾î¸¦ À§ÇÑ Å¸±êÀÌ µÉ °¡´É¼º¿¡ ´ëÇØ °ËÅä ÇØ º¸¾Ò´Ù.
Obesity-induced inflammation is considered to be a potential cause of metabolic disorders such as insulin resistance, type 2 diabetes, and cardiovascular diseases. Various inflammatory components involved in obesity-induced inflammation are known, but the biomolecules and mechanisms underlying the obesity-related inflammation/metabolic diseases remain to be elucidated. Cell surface membrane receptors TNFRSFs (Tumor Necrosis Factor Receptor Superfamily) and their counterpart ligands provide important inflammatory signals through their interaction, and thus have been exploited for therapeutic targets for treating various inflammatory diseases. Recent studies demonstrate that some of the inflammatory receptors/ligands are associated with obesity-induced inflammation and metabolic diseases. In this mini-review, the role of four different inflammatory receptors/ligand (CD40/CD40L, 4-1BB/4-BBL, FN14/TWEAK, HEVM/LIGHT) interactions are discussed along with their potential for therapeutic targets against obesity-related inflammation and metabolic diseases.
Å°¿öµå
ºñ¸¸, ¿°Áõ, ´ë»çÁúȯ, ¿°Áõ¼ö¿ëü/¸®°£µå
Obesity, Inflammation, Metabolic diseases, Inflammatory receptor/ligand
KMID :
0388120140230020083
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)